United States: It's About Time! 10 Key (Needed) Changes Proposed To The Human Subjects Protection "Common Rule"

The world has changed drastically since 1991 when Operation Desert Storm was underway; the USSR crumbled; Prince Charles and Princess Diana separated; the World Wide Web was born; gas cost $1.14; and the Dow peaked at 3168. But until now, the rules and regulations governing human subjects research (the "Common Rule" at 45 C.F.R. Part 46) have not followed suit. On September 8, 2015, 16 federal departments and agencies issued a 519-page Notice of Proposed Rulemaking (NPRM), requesting comments on proposed rules that would update the Common Rule to reduce burden, delay, and ambiguity for clinical research investigators and modernize the research oversight process while still protecting human research subjects.

Below are 10 key (needed) changes to anticipate if the NPRM rules are implemented in their current form (whenever that may be).

1. Redefining "Human Subject" to Include Biospecimens

Three years after publication of the finalized rule, the definition of "Human Subject Research" would change to include biospecimens obtained, used, studied, or analyzed, regardless of whether individually identifiable information about the biospecimen's source may be readily ascertained by the researcher. As a result, most instances of secondary research performed on biospecimens would require informed consent from the patient. If the research is only to generate information about the subject that is already known, such as using the specimen as a control for validation studies, then consent would not be required. When consent would be required for secondary biospecimen research, it could be obtained broadly as described by #2 below. This change is expected to increase subjects' autonomy and control over how their information (including specimens) is used.

Institutional Review Boards (IRBs) would have limited authority to waive the informed consent requirement and would be cautioned never to do so when the research involves biospecimens. Waiver would be permissible when the research could not be carried out practicably without the waiver or alteration because of scientific validity, ethical concerns, or no similar population from which consent can be obtained. Convenience, cost, and speed are to be very minor considerations.

2. Adding Categories of Activities Exempt From Common Rule Oversight

Three broad categories would be established to encompass new exempt activities. These categories vary by the level of documentation, information security, and IRB oversight for the research. These changes are expected to make the IRB review process more efficient for IRBs, administrators, and investigators while still ensuring sufficient safeguards are in place for lower-risk research activities that would not be excluded from Common Rule oversight.

Research that involves low-risk interventions without using any biospecimens or individually identifiable information would simply require documentation of the exemption determination. This may include consumer taste tests, evaluating effectiveness of public benefit programs, or other benign interventions collected through written or verbal responses.

Research that may involve sensitive information would require documentation of the exemption determination and reasonable and appropriate security safeguards (with a checklist to be published at a later date). These research activities may include surveys and interviews recorded with individual identifiers or secondary research using private information where the subject has given consent.

Research involving biospecimens and identifiable information would require documentation of the exemption determination, privacy safeguards, broad consent from the patient, and limited IRB review of the adequacy of the privacy safeguards and process by which broad consent would be sought. Such activities may include storing, maintaining, or using biospecimens or individually identifiable private information for secondary research.

To assist investigators and institutions in making exemption determination decisions, federal departments and agencies would develop exemption determination tools which, if given accurate information, would provide an exemption safe harbor. The government also plans to assist researchers in obtaining broad consent for storing, maintaining, or using biospecimens and individually identifiable private information. The Secretary of the U.S. Department of Health and Human Services (HHS) proposes to develop a broad consent template allowing the subject to consent to future, unspecified research uses of the information or biospecimen.

Of note, if the broad consent template is not used, the exemption would not be available and the consent form would need to be reviewed by the IRB. Additionally, if the researchers plan to return research results to patients, the exemption would not be available.

3. Simplifying Informed Consent Forms

Many consent forms are lengthy tomes filled with complicated legal or medical terminology. The NPRM aims to simplify consent forms, requiring them to list the required elements first, including any HIPAA authorization, with any extraneous information not required by the regulations relegated to an appendix. The consent form would be required to disclose whether individual identifiers will be removed and whether the data will be used for future studies. This may be burdensome on some institutions as there could be a need to develop a system to track limitations of consent and impermissible uses of data.

Additionally, the NPRM poses three new required elements, when applicable: Subjects should (1) be informed when their biospecimens may be used for profit and whether the subject will share in that profit; (2) know if and when clinically relevant results will be disclosed to them; and (3) have the option to consent or refuse future contact by investigators seeking additional information or soliciting additional research studies.

4. Making Consent Forms Publicly Available

Researchers would be required to post on a government website the final version of the informed consent form, including the name of the protocol and relevant contact information, within 60 days after the study is closed to recruitment. This is thought to allow for public scrutiny of the informed consent process.

5. Safeguarding Individually Identifiable Information and Biospecimens

Any research subject to the Common Rule would be required to have reasonable safeguards to protect against security risks or compromising biospecimen integrity. IRBs in possession of individually identifiable information would also be required to implement appropriate safeguards (with a list of acceptable measures to be published at a later date). The NPRM clarifies that if research is already HIPAA-compliant, no additional efforts would be necessary. With creation of a uniform standard, these changes are expected to help ensure that appropriate privacy and confidentiality protections exist without requiring the burden of assigning a committee to review the privacy and confidentiality protections of each study.

6. Using a Single IRB for Cooperative Research

Unless otherwise required by law, all institutions engaged in cooperative research would be required to use a single IRB as the reviewing IRB. Individual institutions would be permitted to continue to use their local IRB, but a single IRB would still be required to oversee the entire study.

Institutions are told not to be concerned about unaffiliated IRBs failing to adhere to Common Rule requirements. Departments and agencies ascribing to the Common Rule would have authority to enforce compliance directly against unaffiliated IRBs that are not operated by an assured institution. Furthermore, institutions would be advised to enter into written agreements with unaffiliated IRBs to establish written procedures to identify the compliance responsibilities of each entity. These changes are expected to streamline the IRB review process for cooperative research studies and give federal agencies and departments a way to hold unaffiliated IRBs accountable for regulatory compliance.

7. Reducing IRBs' Continuing Review Burden

An IRB would no longer be required to continue reviewing studies in the data analysis or clinical follow-up stages unless required by law, provided the IRB receives annual confirmation that the research remains ongoing and no changes have occurred that would require continuing review. Additionally, IRBs would not be required to continue reviewing studies in the third new exemption category that would require limited IRB review at initiation. These reviews are not thought to contribute significantly to human subjects protection yet produce a measurable regulatory burden for researchers.

8. Clarifying "Minimal Risk" Studies Eligible for Expedited IRB Review

To assist IRBs in determining whether a study is of "minimal risk," HHS proposes to publish a list of activities that qualify as minimal risk. This list would be reviewed and updated at least every eight years. IRBs would be required to conduct an expedited review of any activities on the list and document their reasoning and justification when conducting a full review of such activities. This practice is expected to result in consistency between IRBs in making minimal risk determinations.

9. Returning Research Results to Patient Medical Records

The NPRM proposes to encourage IRBs to review an investigator's plan to return individual results to patients' medical records but plans to instruct IRBs not to decide whether such a plan to return those results is needed. Because results may be clinically irrelevant or may cause psychological distress, the NPRM considers this provision an important inclusion in the informed consent process.

10. Expanding Applicability of the Common Rule

If an institution in the United States receives federal support for non-exempt and non-excluded human subjects research, any clinical trial conducted at that institution would be required to be compliant with the Common Rule, regardless of the funding source, unless the research is already subject to FDA oversight. Through implementation of this change, studies posing the most risk to patients would be more likely subject to Common Rule oversight.

The NPRM offers long overdue changes that will benefit from public comment and scrutiny. Please let us know before December 7, 2015 if you would like assistance preparing a comment on the NPRM.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Sheppard Mullin Richter & Hampton
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Sheppard Mullin Richter & Hampton
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions